Baricitinib, approved by the FDA for two inflammatory disorders, rheumatoid arthritis and alopecia areata, selectively inhibits Janus kinase 1 (IC50 = 5.9 nM) and 2 (5.7 nM), over 3 (0.56 µM).1 It thereby blocks JAK/STAT signaling, reducing cytokine release and suppressing the innate and adaptive immune systems.1,2 Was recently shown to significantly improve COVID-19 symptoms in a preliminary human trial, presumably through suppression of the cytokine release syndrome (''cytokine storm) induced by SARS-CoV-2 infection.3
* VAT and and shipping costs not included. Errors and price changes excepted
